News

No survival benefit to bisphosphonate in chemoresistant breast cancer


 

The bisphosphonate zolendronate didn't improve survival in patients with chemoresistant breast cancer, according to results from the phase III NATAN trial.

In an interview at the San Antonio Breast Cancer Symposium, Dr. Gunter von Minckwitz discusses the trial's results and clinical implications, and whether a role remains for bisphosphonates in postmenopausal patients.

The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel.

Recommended Reading

Estrogen Protects Against Breast Cancer Long After Treatment
Breast Cancer ICYMI
Estrogen-Only HT Also Increases Breast Cancer Risk
Breast Cancer ICYMI
The case for chemoprevention as a tool to avert breast cancer
Breast Cancer ICYMI
Breast cancer prevention and Tx: An evidence-based guide
Breast Cancer ICYMI
Can nonhormonal treatments relieve hot flushes in breast Ca survivors?
Breast Cancer ICYMI
UPDATE ON BREAST HEALTH
Breast Cancer ICYMI
Breast cancer hormone therapy may affect cognitive function
Breast Cancer ICYMI
Osteoporosis treatment and breast cancer prevention: Two goals, one treatment?
Breast Cancer ICYMI